{"nct_id":"NCT02707601","title":"Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment","status":"COMPLETED","status_verified_date":"2018-09","start_date":"2016-04-01","start_date_type":"ACTUAL","primary_completion_date":"2017-09-14","primary_completion_date_type":"ACTUAL","completion_date":"2017-09-29","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["GILD"]}